Kavanagh lends marketing experience to Nanosonics’ board
02 August, 2012 by Dylan Bushell-EmblingNewly-appointed Nanosonics (ASX:NAN) director Michael Kavanagh will offer his experience introducing new products into the healthcare market in order to see the company succeed on the world stage.
Start-up gets backing for stroke rehab tool
02 August, 2012 by Dylan Bushell-EmblingUniQuest's latest start-up SMART Arm has secured investment support to launch its eponymous product, a device for improving arm function in stroke victims.
Bioniche developing synthetic cow fertility product
01 August, 2012 by Dylan Bushell-EmblingBioniche Life Sciences (ASX:BNC) could be on the road to developing the world's first entirely synthetic FSH product for increasing fertility rates in cows, proof-of-concept stage data suggests.
pSivida signs first evaluation deal for eye treatment
31 July, 2012 by Dylan Bushell-EmblingpSivida (ASX:PVA) has scored another deal this week, with a major biopharmaceutical company signing up to evaluate the company's Tethadur opthalmic technology.
New ASX listing rules to support maturing biotechs
31 July, 2012 by AusBiotechAs part of a range of initiatives to improve the competitiveness of Australia’s financial markets, the Australian Securities Exchange (ASX) has finalised new listing rules to help make it easier for small to medium size companies to raise capital for investment.
Alchemia set to receive share of profits from fondaparinux sales
31 July, 2012 by Dylan Bushell-EmblingAlchemia Limited (ASX:ACL) is due to start receiving a share of the profits from US sales of its anticoagulant product, generic fondaparinux.
CathRx borrows to cover short term expenses
31 July, 2012 by Tim DeanCathRx (ASX:CXD) has taken a $1m loan to cover short term expenses until it can finalise a more substantial capital raising, due within a couple of months.
Osprey Medical packs $18m cash after IPO
30 July, 2012 by Dylan Bushell-EmblingMedical device company Osprey Medical (ASX:OSP) is still cashed up from its 20 million IPO on the ASX, despite recording a cash outflow for the June quarter of $1.4 million.
Universal Biosensors gets second $1.5m payment
27 July, 2012 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) has earned a second $1.5 million milestone payment from Siemens Healthcare, seven weeks after receiving the first.
AAMRI calls for government to spur biotech commercialisation
27 July, 2012 by Tim DeanThe government has a significant role to play in helping Australia’s world class medical research be translated into genuine health and economic benefits, says the Association of Australian Medical Research Institutes (AAMRI).
Investment event of the year calls for expressions of interest
26 July, 2012 by AusBiotechAusBiotech invites your expression of interest for the opportunity to present at the Australasian Life Science Investment Summit (ALSIS) 2012 as one of 40 of Australasia’s most promising biotechnology companies.
BREVAGen receives approval to sell in California
26 July, 2012 by Tim DeanGenetic Technologies (ASX:GTG) continues its push into the US with BREVAGen, with it gaining approval to sell into California.
CoDa raises NZ$25m to fund wound treatment
26 July, 2012 by Dylan Bushell-EmblingNZ biotech CoDa Therapeutics has received a NZ$24.5 million funding injection from a Russian investor, to help continue commercialisation of wound therapy Nexagon.
Mesoblast eyes human trials of stem cell treatment for rheumatoid arthritis
25 July, 2012 by Dylan Bushell-EmblingAnimal trials of Mesoblast's (ASX:MSB) mesenchymal stem cells in rheumatoid arthritis (RA) have encouraged the company press on with an FDA application for a phase II trial.
AtCor files FDA application for cardiovascular monitor
25 July, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has submitted an application for approval to market its updated SphygmoCor XCEL cardiovascular monitoring system in the US.
